Quest Diagnostics To Buy Shiel To Widen Footprint In NY-NJ
Zacks Investment Research | Oct 01, 2017 09:18PM ET
On an inorganic expansion spree, Quest Diagnostics Incorporated (NYSE:DGX) has recently entered into yet another acquisition agreement. The company has decided to purchase Fresenius Medical Care’s medical laboratory business, Shiel.
Although financial terms of the deal have been kept under wraps, Quest Diagnostics expects the deal to close in the fourth quarter of 2017, subject to customary regulatory approvals.
Notably, Shiel is a clinical laboratory provider of Fresenius Medical Care, a premier healthcare company particularly working on renal and other chronic conditions in patients. The lab specifically serves in the New York-New Jersey metropolitan area.
Per Quest Diagnostics, post completion of the buyout, Shiel will provide broader access to the company’s diagnostic insights and innovations for physicians and patients in the New York-New Jersey region. The takeover is expected to expand Quest Diagnostics’ patient service centers network in the region.
Additionally, care providers will have direct access to Quest Diagnostics’ broader menu of services. The ones currently provided by Shiel’s laboratories in Rockleigh, NJ and Brooklyn, NY, will now shift to the company’s flagship clinical laboratory in Teterboro, NJ.
Quest Diagnostics and Fresenius Medical Care will jointly work on identifying patients with early-stage chronic kidney disease, with potential to benefit from treatment to slow progression to end-stage renal disease (ESRD), based on the former’s laboratory data analytics.
Quest Diagnostics’ merger and acquisition activity is believed to be a key growth driver, functioning in full swing. Notably, the company has been of late focusing on tactics to accelerate growth and drive operational excellence through strategically aligned, accretive acquisitions. Worth reckoning is the company’s recent consolidation with an outreach operation of PeaceHealth Laboratories.
Per the company, these tuck-in acquisitions fit well within the ambit of M&A guidelines. Quest Diagnostics’ takeover plans are consistent with its goal of contributing 1-2% revenue growth annually through accretive acquisitions.
Quest Diagnostics Incorporated Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.